Considerations for developing an immunization strategy with enterovirus 71 vaccine. Issue 9 (25th February 2015)

• Record Type: Journal Article
• Authors: Li, Li; Yin, Hongzhang; An, Zhijie; Feng, Zijian
• Is Part Of: Vaccine. Volume 33:Issue 9(2015)
• Page Start: 1107
• Page End: 1112
• Publication Date: 2015-02-25
• Subjects: Enterovirus 71 -- Hand, foot, and mouth disease -- Vaccine -- Immunization strategy; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2014.10.081
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Enterovirus 71 (EV71) is a common pathogen for hand, foot, and mouth disease (HFMD), which has significant morbidity and mortality, and for which children aged 6–59 months age are at highest risk. Due to lack of effective treatment options, control of EV71 epidemics has mainly focused on development of EV71 vaccines. Clinical trials have been completed on 3 EV71 vaccines, with trial results demonstrating good vaccine efficacy and safety. When EV71 vaccine is approved by China's national regulatory authority, an evidence-based strategy should be developed to optimize impact and safety. An immunization strategy for EV71 vaccine should consider several factors, including the target population age group, the number of doses for primary immunization, the need for a booster dose, concomitant administration of other vaccines, economic value, program capacity and logistics, and public acceptance. Once EV71 vaccines are in use, vaccine effectiveness and safety must be monitored in large populations, and the epidemiology of HFMD must be evaluated to assure a match between vaccination strategy and epidemiology. Evaluation in China is especially important because there are no other EV71 vaccines globally.